Table 2.
Characteristics of patients by renal function and by hepatic function at start of first‐line immune checkpoint inhibitor treatment
| Baseline renal function | Baseline hepatic function | |||||
|---|---|---|---|---|---|---|
| Patient characteristic | Normal (n = 1,838) | Moderate or severe dysfunction (n = 46) | p value | Normal (n = 1,669) | Moderate or severe dysfunction (n = 48) | p value |
| Sex, n (%) | .004 | .696 | ||||
| Female | 584 (31.8) | 5 (10.9) | 514 (30.8) | 13 (27.1) | ||
| Male | 1,254 (68.2) | 41 (89.1) | 1,155 (69.2) | 35 (72.9) | ||
| Median age a (IQR), yr | 69.0 (59.0–77.8) | 78.5 (72.2–82.0) | <.001 | 69.0 (59.0–78.0) | 66.0 (61.0–75.5) | .493 |
| Clinical characteristics, n (%) | ||||||
| Stage at initial diagnosis | .068 | .839 | ||||
| Stage 0 | 8 (0.4) | 0 (0.0) | 8 (0.5) | 0 (0.0) | ||
| Stage I | 155 (8.4) | 0 (0.0) | 135 (8.1) | 2 (4.2) | ||
| Stage II | 344 (18.7) | 9 (19.6) | 312 (18.7) | 9 (18.8) | ||
| Stage III | 412 (22.4) | 11 (23.9) | 362 (21.7) | 9 (18.8) | ||
| Stage IV | 545 (29.7) | 10 (21.7) | 497 (29.8) | 18 (37.5) | ||
| Unknown | 374 (20.3) | 16 (34.8) | 355 (21.3) | 10 (20.8) | ||
| ECOG PS a | .466 | .351 | ||||
| 0 | 450 (24.5) | 10 (21.7) | 436 (26.1) | 13 (27.1) | ||
| 1 | 373 (20.3) | 8 (17.4) | 353 (21.2) | 12 (25.0) | ||
| 2+ | 156 (8.5) | 7 (15.2) | 152 (9.1) | 7 (14.6) | ||
| Missing | 859 (46.7) | 21 (45.7) | 728 (43.6) | 16 (33.3) | ||
| Tumor characteristics, n (%) | ||||||
| BRAF | .307 | .909 | ||||
| Mutation − | 1,043 (56.7) | 29 (63.0) | 953 (57.1) | 30 (62.5) | ||
| Mutation + | 473 (25.7) | 7 (15.2) | 425 (25.5) | 12 (25.0) | ||
| No evidence of testing in EHR prior to treatment | 267 (14.5) | 8 (17.4) | 234 (14.0) | 5 (10.4) | ||
| Unknown or indeterminate | 55 (3.0) | 2 (4.3) | 57 (3.4) | 1 (2.1) | ||
| Treatment characteristics, n (%) | ||||||
| Practice type | .446 | .225 | ||||
| Academic | 297 (16.2) | 5 (10.9) | 168 (10.1) | 2 (4.2) | ||
| Community | 1,541 (83.8) | 41 (89.1) | 1,501 (89.9) | 46 (95.8%) | ||
| Regimen | .086 | .887 | ||||
| ipilimumab | 575 (31.3) | 15 (32.6) | 528 (31.6) | 14 (29.2) | ||
| ipi. + nivolumab | 386 (21.0) | 3 (6.5) | 339 (20.3) | 12 (25.0) | ||
| nivolumab | 361 (19.6) | 13 (28.3) | 332 (19.9) | 9 (18.8) | ||
| pembrolizumab | 516 (28.1) | 15 (32.6) | 470 (28.2) | 13 (27.1) | ||
a
At index date, defined as first‐line therapy start date.
Abbreviations: ECOG PS, Eastern Cooperative Oncology Group Performance Status; EHR, electronic health record; IQR, interquartile range; ipi, ipilimumab.